VRDN
Viridian Therapeutics, Inc.+2.77 (+10.99%) TodayNov 4, 11:43 AM ET
About VRDN
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Company
- Headquarters
- Waltham, MA
- Employees
- 252 (2026)
- Listed
- Jun 18, 2014
- Exchange
- Nasdaq
- Website
- viridiantherapeutics.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #66 of 430
- P/B #139 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.28T+1.74%
- JNJJohnson & Johnson$655.5B+2.31%
- ABBVAbbVie Inc$511.6B+1.22%
- MRKMerck & Co Inc$365.4B+2.38%
- NVSNovartis AG$311.0B+3.40%
Financial summary
Related companies
About
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
From company filings and market data · Not investment advice
Price data
From daily bars
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.